Home › Drug Codes › Q Codes › Q5117 · KANJINTI
Updated July 1st, 2026

KANJINTI Q Code: Q5117

Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg

Login to unlock all benchmarks

Q4 2026 Medicare Payment Limit for Q5117, effective October 1, 2026: $63.871 per HCPCS billing unit, up 5.5% from $60.522. From CMS's final file.

?
Medicare Payment Limit ?
$60.522
/ HCPCS billing unit · Q3 2026
APC Payment Limit ?
$60.522
/ HCPCS billing unit · APC 9330
ASP ?
$•••.••
Login to view
WAC · AWP ?
$•••.••
Login to view
NDCs Crosswalked ?
5
View NDC crosswalk →

Drug & Product Overview

HCPCS Descriptor Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg
HCPCS Added Date October 1, 2019
Manufacturer Amgen
Route of Administration Intravenous
Generic Status Single-Source; Branded
Dosage Type Single-Dose, Multi-Dose
Dosage Form Injection, Powder, Lyophilized, For Solution | Not Available

About KANJINTI

Kanjinti is a medication aligned to the HCPCS Q Code: Q5117 for billing, pricing, and reimbursement purposes in the United States. This Oncology medication is administered via the intravenous route and manufactured by Amgen.

According to CMS Drug Use Information: Trastuzumab is used to treat certain types of breast, stomach, or esophagus cancer. Trastuzumab belongs to a class of medications known as monoclonal antibodies. It works by slowing or stopping the growth of cancer cells. This monograph is about the following trastuzumab products: trastuzumab, trastuzumab-anns, trastuzumab-dkst, trastuzumab-dttb, trastuzumab-pkrb, trastuzumab-qyyp, trastuzumab-strf.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code Drug Manufacturer Billing Units / Pkg Package Size
55513-0132-01 Kanjinti Amgen, Inc 42 420 MG / 20 ML
55513-0132-21 Kanjinti Amgen, Inc 42 420 MG / 20 ML
55513-0141-01 Kanjinti Amgen, Inc 15 150 MG / 7.15 ML
55513-0141-21 Kanjinti Amgen, Inc 15 150 MG / 7.15 ML
55513-0164-01 Kanjinti (Kit) Amgen Inc 42 420 MG
Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.
Login →

KANJINTI Pricing & Reimbursement

Q5117 Private Payer Reimbursement
$52.79 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →
UnitedHealthcare, BlueCross BlueShield, Aetna, Cigna

Historical Graphing and Billing Calculator

per HCPCS unit
As of Q3 2026

Trastuzumab Biosimilar Information:

KANJINTI Approval Date: June 13, 2019

Product Name HCPCS Code Active Ingredient BLA Type
Herceptin J9355 Trastuzumab 351(a) Originator Product
Ogivri Q5114 Trastuzumab 351(k) Biosimilar
Herzuma Q5113 Trastuzumab 351(k) Biosimilar
Ontruzant Q5112 Trastuzumab 351(k) Biosimilar
Trazimera Q5116 Trastuzumab 351(k) Biosimilar
Kanjinti Q5117 Trastuzumab 351(k) Biosimilar
Hercessi Q5146 Trastuzumab 351(k) Biosimilar

KANJINTI Claims Performance

Claims from Jan 2026 – Aug 2026
Claim Denial Rate 17%
Avg. Days to File 11.4days
Avg. Days to Pay 22.6days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore Q5117 claims analytics on FocalPoint →
OnPoint Oncology

KANJINTI CPT Administration Codes

The below list of CPT codes is intended for informational purposes only and may not be exhaustive. CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.

CPT Code Description
96413 Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415 Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)
Not on the CMS JW / JZ list

CMS does not include Kanjinti (Q5117) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing Q5117. Wastage billing guide →

KANJINTI Medically Unlikely Edits (MUE)

The most billing units of Q5117 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 10 mg.

Practitioner Office & Hospital Outpatient
120 units / day
= 1,200 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

mg Enter a dose to see how many billing units it is and whether it is under the limit.

KANJINTI Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Breast Cancer Metastatic Breast Cancer Metastatic Gastric Cancer
Drug Class
HER2/Neu/cerbB2 Antagonists [MoA]HER2/neu Receptor Antagonist [EPC]

Login for BuyandBill.com Analytics

Unlock deeper insights with BuyandBill’s Comparative Report!

  • Compare ASP, WAC, and AWP across drugs.
  • Visualize Drug Price Movement Over Time
  • Tailor reports to drug class, manufacturer, or HCPCS Code.
  • Compare Biosimilar and 505(b)(2) products.
Access Full Report →

Frequently Asked Questions

Is there an available Kanjinti billing and coding guide?
Billing and coding information for KANJINTI can be found through Amgen. Visit Here →
Are there any available Kanjinti patient assistance programs?
KANJINTI patient assistance information can be found through Amgen. Visit Here →
Where can I find Kanjinti prescribing information?
KANJINTI prescribing information can be found at the link below: Visit Here →
Where can I find Kanjinti side effect information?
Information regarding KANJINTI's side effects can be found at MedlinePlus Visit Here →
Does billing KANJINTI require JZ/JW wastage modifiers?
CMS does not include KANJINTI (Q5117) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing Q5117. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.

Related Drug Codes

Explore billing, coding, and pricing for drugs related to KANJINTI.

Q5112ONTRUZANTInjection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mgOrganonAdded July 1, 2019Q5114OGIVRIInjection, trastuzumab-dkst, biosimilar, (ogivri), 10 mgBiocon Biologics IncAdded July 1, 2019J9355HERCEPTINInjection, trastuzumab, excludes biosimilar, 10 mgGenentechAdded January 1, 2000Q5113HERZUMAInjection, trastuzumab-pkrb, biosimilar, (herzuma), 10 mgTevaAdded July 1, 2019Q5116TrazimeraInjection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mgPfizerAdded October 1, 2019Q5146HERCESSIInjection, trastuzumab-strf (hercessi), biosimilar, 10 mgAccordAdded January 1, 2025J9000ADRIAMYCINInjection, doxorubicin hydrochloride, 10 mgMultiple ManufacturersAdded January 1, 1984J9267PaclitaxelInjection, paclitaxel, 1 mgMultiple ManufacturersAdded January 1, 2015J9356HERCEPTIN HYLECTAInjection, trastuzumab, 10 mg and hyaluronidase-oyskGenentechAdded July 1, 2019J9306PERJETAInjection, pertuzumab, 1 mgGenentechAdded January 1, 2014